Apr 21, 2008 by Brian LawlerPfizer Is Still FlounderingGenerics keep pounding away at its sales and profits.
Apr 18, 2008 by Brian LawlerMore Good News About Cancer VaccinesPfizer's deal with Avant for an immunotherapy for brain cancer is promising.
Apr 17, 2008 by Brian LawlerThe End for (Another) Hepatitis C Drug CandidateViroPharma stops development of its compound after data showed it may hurt the liver.
Apr 17, 2008 by Brian LawlerCVT's Copacetic Cash ManagementThe drugmaker signs away a little to get a lot.
Apr 16, 2008 by Brian LawlerCephalon Convinces the ContinentThe pharmaceutical's lead pain drug gets approved for marketing in Europe.
Apr 16, 2008 by Brian LawlerAlpharma's Soothing GuidanceAlpharma lowers its financial guidance for 2008.
Apr 14, 2008 by Brian LawlerA Little Delay Goes Away for CVTThe FDA approves another CV Therapeutics compound.
Apr 14, 2008 by Brian LawlerMannKind Gets Smacked by Big Brother's Bad NewsBad news for a competitor sinks MannKind shares.
Apr 14, 2008 by Brian LawlerPDL BioPharma's Split DecisionThe company will separate its patents from its prospects in drug development.
Apr 11, 2008 by Brian LawlerEnd of the Line for MillenniumTakeda acquires the drugmaker just as it was turning things around.
Apr 11, 2008 by Brian LawlerAmgen's Unsurprising DelayThe FDA extends its review of an Amgen drug candidate.
Apr 10, 2008 by Brian LawlerGlaxo Angers the FDAUpsetting the agency that approves drugs is never a good move.
Apr 10, 2008 by Brian LawlerNektar Can't Squeeze Nectar From This DrugSafety issues sink its inhaled insulin.
Apr 8, 2008 by Brian LawlerNovartis Sees More Growth AheadNovartis makes one of the largest acquisitions in health-care history.
Apr 8, 2008 by Brian LawlerFDA Approvals ... Increase?So far in 2008, the agency's given more drugs a thumbs-up.
Apr 3, 2008 by Brian LawlerCVT in an Explanatory MoodCV Therapeutics presents new data on a lead drug.
Apr 3, 2008 by Brian LawlerWill InterMune's Hepatitis C Drug Compete?InterMune announces positive data for one of its drugs.
Apr 3, 2008 by Brian LawlerA Punch to Gilead's CompetitionA rival compound's bad data signals a better future for Gilead's lead drugs.
